Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
May 04, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 04, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Present at 2022 RBC Capital Markets Global Healthcare Conference
May 03, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 03, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Luxeptinib Preclinical Data Extend Potential Applications from Oncology to Inflammation
May 02, 2022 16:10 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, May 02, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report First Quarter 2022 Financial Results and Hold Conference Call on Monday, May 9, 2022
April 25, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 25, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
Aptose Announces Executive Management Changes
April 07, 2022 07:00 ET
|
Aptose Biosciences, Inc.
─ Appoints Philippe Ledru as Chief Commercial Officer ─ ─ Announces resignation of CFO/CBO Jotin Marango, MD, PhD ─ SAN DIEGO and TORONTO, April 07, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences...
Aptose to Present at Canaccord Genuity’s 2022 Horizons in Oncology Virtual Conference
March 31, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 31, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Reports Results for the Fourth Quarter and Full Year 2021
March 22, 2022 16:01 ET
|
Aptose Biosciences, Inc.
- HM43239 clinical remission at 120mg expands list of potential treatable AML populations - - On track to initiate genotype-enriched expansion program for HM43239 in 2H22 - - Cash runway...
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
March 08, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 08, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage precision oncology company developing highly differentiated oral kinase...
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 01, 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 01, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the...
Aptose to Participate in Two Biotech Events in January 2022
December 29, 2021 07:30 ET
|
Aptose Biosciences, Inc.
— H.C. Wainwright BIOCONNECT Virtual Conference — — 11th Annual LifeSci Partners Corporate Access Event — SAN DIEGO and TORONTO, Dec. 29, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc....